The R144C change in the CYP2C9*2 allele alters interaction of the ctochrome P450 with NADPH:cytochrome P450 oxidoreductase

Pharmacogenetics

Volumn 7, Issue 3, 1997, Pages 203-210

  Crespi, Charles L ^a   Miller, Vaughn P ^a  

^a Gentest Corporation   (United States)

Author keywords

CYP2C9*2; NADPH; P450 oxireductase; R144C

Indexed keywords

CUMENE HYDROPEROXIDE; CYTOCHROME P450 ISOENZYME; DICLOFENAC; LAURIC ACID; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE FERRIHEMOPROTEIN REDUCTASE; WARFARIN;

ALLELE; ARTICLE; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME SUBSTRATE; HUMAN; HUMAN TISSUE; KINETICS; LIVER MICROSOME; LYMPHOBLAST; PRIORITY JOURNAL;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; BENZENE DERIVATIVES; CYTOCHROME P-450 ENZYME SYSTEM; DICLOFENAC; HUMANS; KINETICS; LAURIC ACIDS; LYMPHOCYTES; MICROSOMES; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; NADPH-FERRIHEMOPROTEIN REDUCTASE; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES;

EID: 0030858832     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199706000-00005     Document Type: Article

References (26)

1. Clarke SE, Baldwin SJ, Bloomer JC, Aryton AD, Sozio RS, Chenery RJ. Lauric acid as a model substrate for the simultaneous determination of cytochrome P450 2E1 and 4A in hepatic microsomes. Chem Res Toxicol 1994: 7, 836-842.
2. Crespi CL, Langenbach R, Penman BW. Human cell lines, derived from AHH-1 TK+/- human lymphoblasts, genetically engineered for expression of cytochromes P450. Toxicology 1993: 82, 89-104.
3. Furuya H, Fernandez-Salguero P, Gregory W, Taber H, Steward A, Gonzalez FJ, Idle JR. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 1995: 5, 389-392.
4. Gotoh O. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and nucleotide sequences. J Biol Chem 1992: 267, 83-90.
5. Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of wild-type and 1359L mutant forms. Arch Biochem Biophys 1996: 333, 447-458.
6. 5. Biochem J 1996: 318, 857-862.
7. Jones BC, Hawksworth G, Horne VA, Newlands A, Morsman J, Tute MS, Smith DA. Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase). Drug Metab Disp 1996: 24, 260-266.
8. Kaminsky LS, de Morais SMF, Faletto MB, Dunbar D, Goldstein JA. Correlation of human CYP2C substrate specificies with primary structure-warfarin as a probe. Mol Pharmacol 1993: 43, 234-239.
9. Lee CA, Kadwell SH, Kost TA, Serabjit-Singh CJ. CYP3A4 expressed by insect cells infected with a recombinant baculovirus containing both CYP3A4 and human NADPH-cytochrome P450 reductase is catalytically similar to human liver microsomal CYP3A4. Arch Biochem Biophys 1995: 319, 157-167.
10. Leeman T, Transon C, Dayer P. Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4′-hydroxyation in human liver. Life Sci 1993: 52, 29-34.
11. Mancy A, Broto P, Dijols S, Dansette PM, Mansuy D. The substrate binding site of human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling. Biochemistry 1995: 34, 10365-10375.
12. 5. Arch Biochem Biophys 1994: 310, 367-372.
13. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996: 6, 1-42.
14. 5. FEBS Lett 1994: 346, 241-245.
15. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes II: solubilization, purification and properties. J Biol Chem 1964: 239, 2379-2385.
16. Phillips AH, Langdon RG. Hepatic triphosphopyridine nucleotide cytochrome C reductase: isolation, characterization and kinetic studies. J Biol Chem 1962: 237, 2652-2660.
17. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin HV, Trager WF. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin drug interactions. Chem Res Tox 1992: 5, 54-59.
18. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994: 4, 39-42.
19. 5 in the process. Arch Biochem Biophys 1994: 314, 234-241.
20. Shen AL, Kasper CB. Role of acidic residues in the interaction of NADPH-cytochrome P450 oxidoreductase with cytochrome P450 and cytochrome c. J Biol Chem 1995: 270, 27475-27480.
21. Shen S, Strobel HW. The role of cytochrome P450 lysine residues in the interaction between cytochrome P4501A1 and NADPH-cytochrome P450 reductase. Arch Biochem Biophys 1992: 294, 83-90.
22. Shen S, Strobel HR. Probing the putative cytochome P450- and cytochrome c-binding sites on NADPH-cytochrome P450 reductase by anti-peptide antibodies. Biochemistry 1994: 33, 8807-8812.
23. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals - studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994: 270, 414-423.
24. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf RC. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 1996: 6, 429-439.
25. 359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996: 6, 341-349.
26. Von Wachenfeldt C and Johnson EF. Structures of eukaryotic cytochrome P450 enzymes. In: Ortiz de Montellano PR, ed. Cytochrome P450 Structure, mechanism and biochemistry. New York: Plenum Press, 1995: 183-223.